Internal audits per ISO 19011 evaluate whether the QMS conforms to planned arrangements, regulatory requirements, and the standard, and whether it is effectively implemented and maintained. ISO 13485 clause 8.2.4 requires an audit program planned around the status and importance of processes and previous results, with auditors who do not audit their own work. Findings must be followed by timely corrections and corrective actions, with verification. ISO 19011 provides guidance on audit principles and auditor competence. Under the QMSR, FDA can review internal audit records during inspections.

Why it matters

Auditors must be independent of the activity audited. Findings feed CAPA and management review. ISO 13485 requires a documented program covering all processes on a risk basis.

Common pitfalls

•Failing to establish a risk-based internal audit program can lead to inadequate coverage of critical processes.
•Using personnel to audit their own work compromises auditor independence and the objectivity of audit findings.
•Treating internal audits solely as a compliance check rather than an opportunity for continuous improvement is a common pitfall.
•Inadequate documentation of audit plans, findings, and follow-up actions can result in non-compliance during external inspections.
•Not linking internal audit findings to the CAPA process diminishes their effectiveness in driving corrective actions and improvements.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.